Nivolumab Alone or Plus Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 12 Nov 2018 Planned End Date changed from 1 May 2026 to 1 Nov 2026.
- 12 Nov 2018 Planned primary completion date changed from 1 May 2023 to 1 Nov 2023.